All In Biotech

Free tool

FAERS Monitor: Atacand Hct

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021093 or its brand name (Atacand Hct, Candesartan Cilexetil, Hydrochlorothiazide). Reports on generic versions are filed under their own applications.

Reports

2,609

Serious

2,165

83% of reports

Hospitalization

1,250

Death reported

170

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective311
  • blood pressure increased239
  • hypertension224
  • dizziness196
  • dyspnoea132
  • fatigue126
  • nausea124
  • headache120
  • drug dose omission107
  • fall106
  • malaise103
  • off label use101
  • vomiting99
  • hypotension97
  • asthenia90

Reports by year received

View as table
YearReports
200420
200545
200665
200789
2008103
2009139
2010152
2011376
2012525
2013170
2014127
2015126
201667
201754
201874
201995
202083
202181
202253
202334
202462
202541
202628

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,550 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood pressure increasedSignal23912.611.22,560
hypertensionSignal2248.57.51,496
drug dose omissionSignal1075.24.3364
hypotensionSignal973.93.2208
dizzinessSignal1963.22.8296
fallSignal1062.62.1102
asthenia901.91.640
drug ineffective3111.91.7141
malaise1031.91.643
dyspnoea1321.91.655
vomiting991.71.428
headache1201.51.323
fatigue1261.31.19
nausea1241.31.17
off label use1010.90.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.